Integrated workflow for rapid selection and optimization of hybridoma cell lines

Hybridomas are comprised of the fusion between B-cell splenocytes from antigen-immunized mice and a myeloma tumor cell line result in immortalized antibody-producing clonal cell lines that can be screened for antigen-specific binding. Today, more than half of the commercialized antibody drugs are from hybridoma cell lines, and hybrid hybridomas have been used to produce bispecific monoclonal antibodies. Screening a hybridoma fusion and then subcloning candidate hybrids are time-consuming elements of the monoclonal antibody discovery process (Figure 1).